Subtopic Deep Dive
Neoantigen Identification and Vaccines
Research Guide
What is Neoantigen Identification and Vaccines?
Neoantigen identification involves sequencing tumor mutations and predicting HLA-binding peptides to design personalized cancer vaccines targeting patient-specific tumor neoantigens.
Researchers use whole-exome sequencing and MHC binding algorithms to identify neoantigens, as shown in Ott et al. (2017) with a melanoma vaccine inducing T-cell responses (2772 citations). Clinical trials combine these vaccines with checkpoint inhibitors for enhanced efficacy. Over 10 key papers from 2007-2020 detail methods and outcomes.
Why It Matters
Personalized neoantigen vaccines enable tumor-specific immunity without autoimmunity, demonstrated in Ott et al. (2017) where vaccination post-checkpoint blockade yielded durable melanoma responses. Van Rooij et al. (2013) linked neoantigen-specific T-cells to ipilimumab success in melanoma (795 citations). These approaches synergize with PD-1 inhibitors, improving survival in refractory cancers (Waldman et al., 2020).
Key Research Challenges
Neoantigen Prediction Accuracy
Algorithms like NetMHC underpredict immunogenic neoantigens due to processing and presentation variability. Ott et al. (2017) vaccinated with 20 predicted neoantigens, but only subsets elicited responses. Validation requires patient HLA typing and T-cell assays.
Tumor Heterogeneity
Intratumor mutation diversity reduces vaccine coverage, as subclonal neoantigens evade immunity. Li et al. (2016) analyzed tumor immunity across samples, showing heterogeneous immune infiltrates (2708 citations). Multi-region sequencing is needed for comprehensive targeting.
Immunosuppressive Microenvironment
Tumor immune evasion via checkpoints limits vaccine efficacy, addressed by combining with anti-PD-1. Binnewies et al. (2018) mapped TIME components hindering therapy (5583 citations). Synergy requires timing and biomarker selection.
Essential Papers
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · 2018 · Nature Medicine · 5.6K citations
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · 2020 · Nature reviews. Immunology · 3.9K citations
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott, Zhuting Hu, Derin B. Keskin et al. · 2017 · Nature · 2.8K citations
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Bo Li, Eric A. Severson, Jean‐Christophe Pignon et al. · 2016 · Genome biology · 2.7K citations
We develop a computational approach to study tumor-infiltrating immune cells and their interactions with cancer cells. Our resource of immune-infiltrate levels, clinical associations, as well as pr...
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Yuanyuan Zhang, Zemin Zhang · 2020 · Cellular and Molecular Immunology · 2.6K citations
Abstract Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoin...
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo González, Catharina Hagerling, Zena Werb · 2018 · Genes & Development · 2.1K citations
The presence of inflammatory immune cells in human tumors raises a fundamental question in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor development can ...
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman · 2020 · Annual Review of Pathology Mechanisms of Disease · 2.1K citations
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) fo...
Reading Guide
Foundational Papers
Start with van Rooij et al. (2013) for neoantigen-T-cell reactivity in immunotherapy response, then Swann and Smyth (2007) for immune surveillance basics (1421 citations).
Recent Advances
Study Ott et al. (2017) for clinical vaccine trial, Waldman et al. (2020) for T-cell mechanisms (3941 citations), and Binnewies et al. (2018) for TIME context (5583 citations).
Core Methods
Whole-exome sequencing, NetMHC binding prediction, tetramer-validated T-cell responses, combined with checkpoint blockade.
How PapersFlow Helps You Research Neoantigen Identification and Vaccines
Discover & Search
Research Agent uses searchPapers('neoantigen vaccine melanoma Ott') to retrieve Ott et al. (2017), then citationGraph to map 2772 citing works on vaccine trials, and findSimilarPapers to uncover van Rooij et al. (2013) neoantigen-TCR links.
Analyze & Verify
Analysis Agent applies readPaperContent on Ott et al. (2017) to extract neoantigen selection criteria, verifyResponse with CoVe against van Rooij et al. (2013), and runPythonAnalysis to plot HLA-binding affinities from supplementary data using pandas, with GRADE scoring clinical response evidence.
Synthesize & Write
Synthesis Agent detects gaps in neoantigen-TIME integration from Binnewies et al. (2018), flags contradictions between prediction tools; Writing Agent uses latexEditText for methods sections, latexSyncCitations for 20+ references, and latexCompile for trial protocol manuscripts with exportMermaid for vaccine design flowcharts.
Use Cases
"Analyze neoantigen immunogenicity scores from Ott 2017 supplementary data"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas affinity thresholding, matplotlib ROC curves) → researcher gets CSV of top immunogenic peptides with statistical p-values.
"Draft LaTeX review on neoantigen vaccines combined with checkpoint inhibitors"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Ott 2017, Waldman 2020) → latexCompile → researcher gets PDF manuscript with formatted figures and bibliography.
"Find code for HLA neoantigen binding prediction from recent papers"
Research Agent → searchPapers('neoantigen prediction') → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → researcher gets annotated GitHub repos with NetMHC pipelines and usage examples.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'neoantigen vaccine trial', structures report with Ott et al. (2017) as anchor, and GRADEs evidence tiers. DeepScan's 7-step chain verifies neoantigen-HLA predictions against van Rooij et al. (2013) with CoVe checkpoints. Theorizer generates hypotheses on neoantigen synergies with ICIs from Binnewies et al. (2018).
Frequently Asked Questions
What is neoantigen identification?
It sequences tumor DNA to find patient-unique mutations, predicts HLA-binding peptides, and validates immunogenicity via T-cell assays.
What methods predict neoantigen binding?
Tools like NetMHC and MHCflurry score peptide-MHC affinity; Ott et al. (2017) used them to select 20 neoantigens for melanoma vaccination.
What are key papers?
Ott et al. (2017, Nature, 2772 citations) on melanoma vaccine; van Rooij et al. (2013, 795 citations) on neoantigen T-cells in ipilimumab response.
What are open problems?
Improving prediction for low-affinity neoantigens, overcoming tumor heterogeneity, and optimizing vaccine-checkpoint combinations for solid tumors.
Research Cancer Immunotherapy and Biomarkers with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neoantigen Identification and Vaccines with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers